Page last updated: 2024-08-17

quinoxalines and Cystadenocarcinoma, Mucinous

quinoxalines has been researched along with Cystadenocarcinoma, Mucinous in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aoki, K; Arimoto, T; Fujii, T; Fukuda, T; Ikeda, Y; Inaba, K; Kashiyama, T; Kawana, K; Makii, C; Miyasaka, A; Oda, K; Osuga, Y; Sone, K; Wada-Hiraike, O; Yano, T	1

Other Studies

1 other study(ies) available for quinoxalines and Cystadenocarcinoma, Mucinous

Article	Year
Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging. Oncotarget, 2016, May-17, Volume: 7, Issue:20 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cystadenocarcinoma, Mucinous; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorescence Resonance Energy Transfer; Humans; MAP Kinase Kinase Kinases; Models, Theoretical; Niacinamide; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases	2016

Article

Year

Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.

Oncotarget, 2016, May-17, Volume: 7, Issue:20

Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cystadenocarcinoma, Mucinous; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorescence Resonance Energy Transfer; Humans; MAP Kinase Kinase Kinases; Models, Theoretical; Niacinamide; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases

2016